# A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

> **NCT07647510** · PHASE3 · RECRUITING · sponsor: **Dianthus Therapeutics** · enrollment: 195 (estimated)

## Conditions studied

- Myasthenia Gravis, Generalized

## Interventions

- **DRUG:** Claseprubart
- **DRUG:** Placebo
- **COMBINATION_PRODUCT:** Claseprubart
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT07647510
- **Lead sponsor:** Dianthus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2028-12
- **Final completion:** 2031-09
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647510, "A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*